EMA Cited · Electrolytes · Oncologic emergency

Hypercalcemia

Updated Oct 31, 2026Adults · ED management12 sources · 9 checked in PubMed2 figuresSociety for Endocrinology 2016 · Endocrine Society 2023

Bottom line

Adjust for albumin, then grade it. Under 12 mg/dL (3.0 mmol/L) rarely needs urgent correction; 12–14 mg/dL usually needs prompt treatment; over 14 mg/dL (3.5 mmol/L) needs urgent correction.¹
Saline first: 0.9% saline, typically 4–6 L over 24 hours, watching for overload in older patients and kidney impairment.^1,2
No routine furosemide. It doesn't lower calcium reliably; keep it for fluid overload.^1,2,7
Then an antiresorptive. In cancer, give an IV bisphosphonate or denosumab (strong recommendation). Zoledronic acid takes 2–4 days to reach its full effect, so add calcitonin for severe cases.^1,2
Find the cause: PTH sorts most cases. Primary hyperparathyroidism and cancer cause 90%.¹ In cancer, median survival after hypercalcemia was 30 days in one series, so discuss goals of care.¹²

Severity

Mild< 12mg/dL

Moderate12–14mg/dL

Severe> 14mg/dL

Albumin-adjusted total calcium. Mild is under 3.0 mmol/L, moderate 3.0–3.5 mmol/L, severe over 3.5 mmol/L.^1,2 A moderate level may be tolerated if it rose slowly.¹

Symptoms: thirst and polyuria; anorexia, nausea and constipation; mood change, confusion and coma; kidney injury; pancreatitis and peptic ulcer; muscle weakness.¹
In the ED, symptoms are vague. In one series, 26% of hypercalcemic patients had symptoms, most often weakness, nausea and disorientation.³ In severe cases, neuropsychiatric (35%) and gastrointestinal (24%) symptoms led.⁴
ECG: the main change is a short QT interval. Osborn (J) waves can appear when severe, and VF arrest has been reported with extreme levels.⁶

Sources disagree

How dangerous is a very high calcium in the first hours? The Society for Endocrinology advises urgent correction over 3.5 mmol/L (14 mg/dL) because of the risk of arrhythmia and coma.¹ In a French ED, 31 patients with calcium above 4 mmol/L (16 mg/dL) had no life-threatening arrhythmia during their ED stay, and calcium did not correlate with QTc. But 55% were dead at 1 year.⁵ LITFL shows a VF arrest at 6.1 mmol/L (24 mg/dL).⁶

First steps

Confirm and adjust total calcium for albumin.¹
Assess symptoms, cognition, volume status and the ECG.¹
Send phosphate, PTH, urea and electrolytes.¹
Rehydrate with IV 0.9% saline.^1,2
Add an antiresorptive if more is needed after saline, or straight away in cancer-related hypercalcemia.^1,2
Look for the cause: drugs and supplements, weight loss, night sweats, cough, and the neck, chest, breasts, abdomen and lymph nodes.¹

FIG 1 · Decision flowCited

Albumin-adjusted calcium high. Check symptoms, volume status and the ECG; send phosphate, PTH and kidney function.¹
Calcium 12 mg/dL (3.0 mmol/L) or more, or symptoms?
No
Usually no urgent correction. Review drugs and supplements and find the cause.¹
Yes
IV 0.9% saline, typically 4–6 L over 24 hours, aiming for urine output of 100–150 mL/h. Watch for overload in older patients and kidney impairment.^1,2
No routine furosemide. Use it only for fluid overload.^1,2,7
Over 14 mg/dL (3.5 mmol/L)?
Yes
Add calcitonin 4 units/kg SC or IM every 12 h, for 48–72 h only.^2,9
Severe kidney failure: consider dialysis.¹
Either way
Antiresorptive if saline isn't enough, or in cancer: zoledronic acid 4 mg IV over 15 min, or denosumab 120 mg SC. Adjust zoledronic acid for kidney impairment.^1,2
Lymphoma, granulomatous disease or vitamin D excess?
Yes
Add a glucocorticoid: prednisolone 40 mg daily, usually effective in 2–4 days.¹
Then
Recheck over days. Calcium bottoms out 2–4 days after a bisphosphonate. Refractory after a bisphosphonate: denosumab.^1,2,10

FIG 1High calcium in the ED. Drawn for this page from the Society for Endocrinology emergency guidance, the Endocrine Society guideline and the FDA labels cited below. Each box carries its own citations.^1,2,9,10

Treatment

Treatment	Adult dose	Onset	Notes
Rehydrate
0.9% saline IV	1–2 L bolus, then 200–500 mL/h; typically 4–6 L over 24 h	Immediate	Lowers calcium about 1–1.5 mg/dL over 24 h. Target urine output 100–150 mL/h.^1,2
Furosemide	Not routine	—	Only for fluid overload after volume repletion. Case reports only.^1,2,7
Quick, short-lived
Calcitonin (salmon)	4 units/kg SC or IM every 12 h; up to 8 units/kg every 6 h	4–6 h	Lowers calcium 1–2 mg/dL. Tachyphylaxis after 48–72 h.^2,9
Antiresorptives
Zoledronic acid	4 mg IV over 15 min	48–72 h	Normalizes calcium in 80–90%; effect lasts 4–6 weeks. Adjust and infuse more slowly if GFR < 60 mL/min.^1,2
Pamidronate	30–90 mg IV at 20 mg/h, by severity	48–72 h	Normalizes calcium in 60–70%. Kidney risk if GFR < 30–35 mL/min.^1,2
Denosumab	120 mg SC; repeat days 8 and 15, then every 4 weeks	3–10 days	Labeled for bisphosphonate-refractory hypercalcemia of malignancy. Causes more hypocalcemia.^2,10
Specific causes
Prednisolone	40 mg daily	2–4 days	Lymphoma, granulomatous disease, vitamin D excess.¹
Cinacalcet	30 mg twice daily, titrated	2–3 days	Parathyroid carcinoma; specialist use.²
Dialysis	Nephrology decision	—	Consider with severe kidney failure.¹

Unreviewed doses. Verify against the current label and your institution's protocol before giving anything.

FIG 2Why you need more than one drug. Drawn for this page from the Endocrine Society guideline's onset times and the Society for Endocrinology's nadir timing.^1,2 Times are approximate and vary between patients.

Sources disagree

Bisphosphonate or denosumab first? The Endocrine Society suggests denosumab over an IV bisphosphonate in cancer, a conditional recommendation on very low certainty evidence with no head-to-head trial.² The Society for Endocrinology lists IV bisphosphonates first and denosumab as a specialist second-line option.¹ The US label covers denosumab only for bisphosphonate-refractory hypercalcemia of malignancy.¹⁰

Zoledronic acid beat pamidronate. In two pooled trials (n = 287), complete response by day 10 was 88.4% with zoledronic acid 4 mg versus 69.7% with pamidronate 90 mg. Responses lasted a median 32 versus 18 days.⁸
Denosumab works after bisphosphonate failure. In 33 patients still hypercalcemic after a bisphosphonate, 64% reached 11.5 mg/dL or less by day 10, with a median response of 104 days.¹¹
Calcitonin for severe cases is a conditional suggestion. The only study found higher mortality in the combination group, and the panel could not judge the balance of benefit and harm.²
Bisphosphonates can overshoot. They can cause hypocalcemia in vitamin D deficiency or when PTH is suppressed.¹

Causes

PTH sorts it. High calcium with high PTH points to primary or tertiary hyperparathyroidism. High calcium with low PTH points to cancer or a rarer cause.¹
In the ED, cancer leads. Malignancy caused 44% and hyperparathyroidism 20% in one series.³ In severe cases, cancer caused 40%, mostly lung, myeloma and renal cell carcinoma, and 36% took calcium supplements.⁴
Rarer causes: thiazides, lithium, granulomatous disease, thyrotoxicosis, vitamin D or A excess, milk-alkali syndrome, immobilization, adrenal insufficiency, theophylline, pheochromocytoma.¹
Cancer types: hypercalcemia affects an estimated 2–30% of patients with cancer, most often breast, lung and renal cancer and myeloma.²

Disposition

Plan for days, not hours. Calcium reaches its low point 2–4 days after a bisphosphonate.¹
Prognosis in cancer is poor. Median survival was 30 days in 126 treated patients, or 135 days when anticancer therapy was available.¹² In a US database of nearly 5,000 patients, in-hospital mortality was 6.8%.²
Treatment still helps symptoms. Polyuria and thirst improved in 83% and CNS symptoms in 71%, and many patients could go home.¹²
Primary hyperparathyroidism with a severe, resistant calcium: parathyroidectomy can be considered.¹
Write it down. Hypercalcemia went unmentioned in 38% of discharge reports in one ED cohort.⁴

Pitfalls

Reading the total calcium without adjusting for albumin.¹
Giving furosemide before the patient is volume replete, or instead of an antiresorptive.^1,2,7
Relying on calcitonin past 72 hours.²
Full-dose zoledronic acid at full speed in kidney impairment.^1,2
Missing calcium supplements and over-the-counter vitamins in the history.^1,4
Forgetting goals of care in advanced cancer.¹²

How strong is the evidence?

Every Endocrine Society recommendation rests on very low certainty evidence. Only the use of a bisphosphonate or denosumab at all is a strong recommendation.² Zoledronic acid's advantage over pamidronate comes from randomized trials.⁸ Furosemide rests on case reports from before bisphosphonates.⁷ The risk of early arrhythmia comes from a single small ED cohort.⁵

On-shift teaching

Questions to ask a learner at the bedside. Tap a question to see the answer. Every answer uses facts cited above.

Q1Why is furosemide no longer routine in hypercalcemia?

The evidence is only case reports from before bisphosphonates, and it doesn't lower calcium reliably. Keep it for fluid overload after volume repletion.^1,7

Q2Saline is running. Why add calcitonin in a calcium of 15 mg/dL?

Zoledronic acid takes 48–72 hours to work. Calcitonin starts within 4–6 hours, but tachyphylaxis limits it to 48–72 hours.²

Q3Zoledronic acid or pamidronate?

Zoledronic acid. Complete response by day 10 was 88.4% versus 69.7%, and responses lasted longer (32 vs 18 days).⁸

Q4Which single blood test sorts most causes?

PTH. High PTH means primary or tertiary hyperparathyroidism; low PTH means cancer or a rarer cause.¹

Q5When are steroids the right drug?

For lymphoma, granulomatous disease or vitamin D excess. Prednisolone 40 mg daily usually works in 2–4 days.¹

Q6What ECG change goes with hypercalcemia?

A short QT interval. Osborn waves can appear when it is severe.⁶

References

Evidence base

What this page is built on

12 sources, cited 98 times. Dots are sources, filled by how far each was read; stronger color means a larger share of the citations. Tap a tier to see its sources.

Read in full · 5Abstract read · 7Record only · 0Link checked · 0

Checked by the writer, not a physician. The dots show how each source was read, not that anyone has confirmed the claims.

1
Walsh J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology endocrine emergency guidance: emergency management of acute hypercalcaemia in adult patients. Endocr Connect. 2016;5(5):G9–G11.GuidelinePMID 27935816 PMCFull text read
2
El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):507–528.GuidelinePMID 36545746 DOIFull text read
3
Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med. 2013;31(4):657–660.CohortPMID 23246111PubMed
4
Ravioli S, Lafranchi A, Exadaktylos AK, Haidinger M, Lindner G. Characteristics and outcome of severe hypercalcemia on admission to the emergency department: a retrospective cohort study. Swiss Med Wkly. 2023;153:40069.CohortPMID 37191138PubMed
5
Guimard C, Batard E, Lavainne F, Trewick D. Is severe hypercalcemia immediately life-threatening? Eur J Emerg Med. 2018;25(2):110–113.CohortPMID 28338532PubMed
6
Burns E, Buttner R. Hypercalcaemia. Life in the Fast Lane, ECG Library; 2024.FOAMlitfl.comPage read
7
LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149(4):259–263.ReviewPMID 18711156PubMed
8
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558–567.RCTPMID 11208851PubMed
9
Miacalcin (calcitonin salmon) injection. US prescribing information. DailyMed.Drug labeldailymed.nlm.nih.govLabel text read
10
Xgeva (denosumab) injection. US prescribing information. DailyMed.Drug labeldailymed.nlm.nih.govLabel text read
11
Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144–3152.CohortPMID 24915117 PMCPubMed
12
Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990;112(7):499–504.CohortPMID 2138442PubMed

Not for clinical use

AI-generated draft. Not reviewed by a physician. This page is for education only and may contain errors, including in doses. Do not use it to diagnose, treat or make decisions about any patient. Rely on your own clinical judgment, your institution's protocols and current drug labeling. Reading this page does not create a physician-patient relationship. Full terms